To the Editor:

Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by *Mycobacterium tuberculosis* antigens without evidence of clinically manifested active TB \[[@C1]\]. The World Health Organization (WHO) estimates that one-third of the global population is infected by *Mycobacterium tuberculosis* \[[@C2]\]. They cannot transmit tuberculosis (TB), but they can develop the disease and become infectious with a life-time risk of approximately 5--15% \[[@C3]\]. A significant proportion of new TB patients, especially in low burden countries, are presumed to occur from the pool of individuals with LTBI.

Treatment of LTBI by isoniazid and/or rifamycin can reduce the risk of future disease by 60--90% \[[@C4]\]. Systematic testing and treatment of LTBI is recommended in several at-risk populations with a favourable trade-off between benefits and harms of treatment. As the majority of individuals undergoing LTBI treatment would never develop TB, regardless of therapy, it is mandatory to minimise risks during treatment. Specifically, it is imperative to design a mechanism to regularly monitor and manage adverse events.

Drug-specific adverse reactions can occur with isoniazid (asymptomatic elevation of serum liver enzyme concentrations, peripheral neuropathy and hepatotoxicity); rifampicin and rifapentine (cutaneous reactions, hypersensitivity reactions, gastrointestinal intolerance and hepatotoxicity). A meta-analysis involving 38 257 subjects treated with isoniazid, estimated the risk of clinical hepatitis at six per 1000 treated individuals (range among the six studies: 0.0--2.9%) \[[@C5]\]. Later, the risk of isoniazid-related symptomatic hepatitis was estimated as 1--3, that of mortality 0--0.3 and that of hospitalisation 0.1--0.2 per 1000 treated persons \[[@C6]\]. More recently, among 24 221 participants in a large trial that was conducted in South Africa, 132 possible adverse events (0.54%) were reported among 130 individuals. Clinical hepatotoxicity was associated with the consumption of alcohol \[[@C7]\]. Evidence shows that the rate of adverse events, in particular death, decreased with time, probably due to better clinical care \[[@C8]\].

We performed a systematic review on the best clinical approach to monitor toxicity in individuals treated for LTBI to inforzm the WHO process for the development of the LTBI management guidelines \[[@C9]\]. The outcome measurements were: mortality and morbidity related to toxicity and tolerability of the preventive therapy. All the outcomes would have been evaluated under different proposed monitoring conditions (*i.e.* "wait and see", clinical and/or biochemical monitoring).

All pertinent studies, limited to English, French and Spanish languages, regardless of geographical setting, were considered. The search had no time limitations and included the following keywords combined in specific strings: TB, LTBI, toxicity, adverse events, safety, tolerability, anti-TB drugs, and preventive therapy. The search was conducted in the electronic databases PUBMED and EMBASE, and, then, expanded to the reference lists of relevant studies and review articles. All the retrieved records were electronically collected and selected on the basis of pre-defined inclusion criteria *i.e.* study design (cross-sectional, case-control, and retrospective/prospective cohort studies or clinical trials), type of participants (individuals with suspected LTBI, tuberculin skin test and/or interferon-γ positive release assay), types of interventions ("wait and see" approach, clinical monitoring, biochemical monitoring, clinical and/or biochemical monitoring), and exclusion criteria, *i.e.* type of manuscripts (letters, editorials, commentaries, case- or series-reports, and publications not written in English, French and Spanish). Findings were reported in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement in an *ad hoc* electronic form \[[@C10]\].

After removing duplicates from the 102 titles identified, 43 records were screened. Only two full text articles were finally assessed for eligibility, both of which were excluded because they did not focus on monitoring approach comparison. In conclusion, our search failed to identify any study providing direct evidence on best practices for clinical monitoring of LTBI treatment.

Therefore, we reviewed 12 purposefully selected national LTBI guidelines from low-incidence countries, which were issued after 2003. Five guidelines (UK, Germany, Switzerland, Spain and Japan) were excluded from further analysis due to the lack of information on monitoring adverse events. A summary of the recommendations from the remaining seven guidelines \[[@C11]--[@C17]\] is reported in the [table 1](#TB1){ref-type="table"}. TABLE 1Main recommendations on interventions for clinical and laboratory monitoring of individuals receiving treatment for latent tuberculosis infection**InterventionRecommendationCountry \[ref\]Clinical monitoring**At baseline and at monthly intervals during treatment.Canada \[11\], USA \[12, 13\], France \[14\], Portugal \[15\], Sweden \[16\], Ireland \[17\]**Laboratory assessment  at baseline^\#^**Only recommended for individuals who are candidates for treatment  aged \>35 years.Canada \[11\]Only recommended for individuals who are candidates for treatment with  risk factors^¶^.USA (CDC) \[12\]Only recommended for individuals who are candidates for treatment with  risk factors^+^.ATS (ATS) \[13\]Only recommended for individuals who are candidates for treatment aged \>35 years  and those with risk factors^§^.Portugal \[15\]Suggested for individuals who are candidates for treatment aged \>14 years.Recommended for all individuals who are candidates for treatment \>35 years and  for those with risk factors^ƒ^.Ireland \[17\]**Laboratory assessment  during treatment^\#^**In case of symptoms: if aged 35--50 years, systematic testing should occur once  at completion at 1 month. Monthly testing for all those aged \>50 years who  have risk factors^\#\#^.Canada \[11\]In case of symptoms and for those with baseline abnormal values, otherwise  monthly for those with risk factors^¶^.USA (CDC) \[12\]In case of symptoms, or monthly for all those aged \>35 years, those with abnormal  baselines values for a liver function test, or those with risk factors^+^.USA (ATS) \[13\]Every 2--4 weeks for those with HBeAG positivity.USA (ATS) \[13\]Only recommended at 2 and 4 weeks after the start of therapy and monthly  thereafter for those aged \>65 years and those with risk factors^¶¶^.France \[14\]Monthly for those aged \>35 years or with risk factors^§^.Portugal \[15\]Systematic testing of all those receiving treatment twice during the first month,  monthly thereafter in adults and every second month in children.Sweden \[16\]Some experts recommend testing every 2--4 weeks for the first 2--3 months  of treatment.Ireland \[17\][^1]

Interventions to monitor adverse events were grouped into three major categories: clinical monitoring, laboratory assessment at baseline and laboratory monitoring during treatment. However, it was noted that the recommendations were consistently based on expert opinion rather than direct evidence from clinical trials.

All the seven guidelines \[[@C11]--[@C17]\] consistently recommend baseline evaluation with information on potential undesired drug events, monthly interaction between healthcare providers and the individual on treatment either through physical visit or telephone contact. Additionally, individuals on treatment should inform healthccare providers should there be signs or symptoms such as jaundice, abdominal pain, nausea or fever, which should result in physical examination and investigation of liver transaminases and bilirubin. Baseline evaluation should include information on potential undesired drug events ([table 1](#TB1){ref-type="table"}).

Routine baseline laboratory testing prior to starting treatment is only recommended for selected subgroups of candidates to treatment. Some guidelines (*e.g.* Canada, Portugal, and Ireland) recommend baseline testing in all subjects aged ≥35 years \[[@C11], [@C15], [@C17]\]. Guidelines from the USA recommend baseline testing only in the presence of risk factors \[[@C12], [@C13]\], whereas guidelines from Portugal and Ireland use both risk factors and age \[[@C15], [@C17]\]. The risk factors described in the guidelines were not consistent ([table 1](#TB1){ref-type="table"}).

Laboratory evaluation during treatment is usually recommended in cases where signs or symptoms described above were found and for individuals with abnormal baseline liver function test results. In addition, several guidelines recommend systematic testing at monthly intervals for selected individuals, the criteria being again age and the presence of risk factors ([table 1](#TB1){ref-type="table"}).

The findings of this comprehensive review demonstrate that a relevant clinical and public health issue, such as clinical monitoring of individuals treated for LTBI, has not been adequately explored and standardised and largely depends on expert opinion, clinical practice and availability of resources. Decisions concerning who to prioritise for laboratory monitoring, what to monitor, and the ideal timing of monitoring are cases in point.

Toxicity monitoring may constitute a substantial proportion of the cost associated with preventive therapy, and economic, human, and financial sustainability may represent a key issue in limiting a wide implementation of programmatic LTBI management. As the newly released WHO guidelines on LTBI management are likely to result in scaling up of the treatment of LTBI, particularly in resource-rich and low-TB incidence settings, it is imperative that programmes design strategies for the implementation of science research to identify the best and cost-effective approach for clinical monitoring of adverse events.
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[^1]: HBeAG: a hepatitis B antigen protein. ^\#^: includes measurements of transaminases and bilirubin in all guidelines. In addition, references \[[@C16], [@C17]\] include complete blood counts in case of rifampicin treatment, and reference \[[@C13]\] include: screening for viral hepatitis in intravenous drug users, born in endemic areas, HIV-infected, sexual or household contact with chronically infected, occupational exposure, chronic haemodialysis, recipients of clotting factors before 1987, have undiagnosed liver disease, are recipients of blood or solid organ transplants before 1992, and are infants born to infected mothers. ^¶^: risk factors in reference \[[@C12]\] include: liver disorders, history of liver disease (*e.g.* hepatitis B or C, alcoholic hepatitis, or cirrhosis), regular use of alcohol, risks for chronic liver disease, HIV infection, pregnancy, immediate *post partum* period, and exposure to drugs for chronic medical conditions. ^+^: risk factors in reference \[[@C13]\] include: possible liver disorders, history of chronic liver disease, regular use of alcohol, HIV infection treated with highly active antiretroviral therapy, pregnancy, immediate *post partum* period, and exposure to drugs for chronic diseases. ^§^: risk factors in reference \[[@C15]\] include: HIV infection, regular use of alcohol, pregnancy, immediate *post partum* period, liver disorders, and exposure to drugs for chronic diseases. ^ƒ^: risk factors in reference \[[@C17]\] include: HIV infection, regular use of alcohol, pregnancy, immediate *post partum* period, history of hepatitis, liver disease or heavy alcohol ingestion, *i.v.* drug use, and treatment with other potential hepatotoxic agents. ^\#\#^: risk factors in reference \[[@C11]\] include: pregnancy or first 3 months *post partum*, history of previous drug-induced hepatitis, current cirrhosis or chronic active hepatitis of any cause, hepatitis C, hepatitis B with abnormal transaminases, daily alcohol consumption or concomitant treatment with other hepatotoxic drugs (*e.g.* methotrexate). ^¶¶^: risk factors in reference \[[@C14]\] include: regular use of alcohol, other liver disorders, poor nutritional status, and history of chronic liver disease (including viral hepatitis infection).
